Alpha Tau Medical

04/02/2026

On , we stand with patients and their families as we continue to pursue our mission to advance worldwide and to offer hope for those who need it most.

02/02/2026

New Horizons for Recurrent Skin Cancer Treatment
As featured in : "Less Invasive Skin Cancer Treatments"

Finding the right treatment for recurrent cutaneous squamous cell carcinoma ( ) can be a challenging journey, especially when traditional surgical options may not be the ideal path for every patient. For many patients, the challenge is finding a treatment that delivers clinical effectiveness while preserving quality of life, particularly in sensitive or previously treated areas.

Alpha Tau Medical is proud to spotlight the work of Dr. Jacob Beer, who is leading a pivotal clinical trial featuring our innovative ® technology. This approach uses highly localized, designed to target tumors from within while potentially minimizing impact on surrounding healthy tissue.

Through the clinical trial, we are working to expand access to new treatment pathways for patients with recurrent cSCC who may have limited options. At the same time, we aim to equip clinicians with an additional, precision-focused tool to address complex cases and advance patient-centered cancer care.

Alpha DaRT treatment for recurrent cSCC is currently available only as part of a clinical trial in the US.

For more information, please contact info@alphatau.com

Not to be the cloud in our sunny Florida sky, but it’s well known that our state has some of the highest rates of skin cancer in the country. Our year-round sunshine and strong ultraviolet (UV) exposure put residents at elevated risk. But skin cancer, particularly recurrent skin cancer, isn’t ju...

29/01/2026

Alpha Tau Medical Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal trial as well as trials in cancers of internal organs including the pancreas and brain -

- Ramping U.S. manufacturing for commercial readiness -

To see the full letter, please read:

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

20/01/2026

Alpha Tau Medical at 2026 - Advancing Combination Therapy in Head and Neck Cancer

Following the release of promising interim clinical trial data studying the Alpha DART® in combination with pembrolizumab as a treatment for locally advanced and metastatic , Alpha Tau continues to see strong interest in this clinical program. Prof. Aron Popovtzer, MD, Chair of the Sharett Institute of Oncology at Hadassah Medical Center and lead investigator of the study, will be attending the Multidisciplinary Head and Neck Cancers Symposium (MHNCS), February 19–21, 2026, in Palm Desert, California.

Prof. Popovtzer will be available to share insights and discuss potential collaboration opportunities related to the Alpha DART and pembrolizumab combination approach. We welcome meetings with colleagues interested in learning more. Please direct message us or email info@alphatau.com to connect.

19/01/2026

The United States is observing Rev. Dr. Martin Luther King Jr. Day, but the principles which are commemorated on this day extend far abroad as well. His legacy emphasized human dignity as central to progress. In medicine, these ideas are reflected in a growing focus on treating patients as individuals rather than simply as cases.

Alpha Tau Medical believes deeply in these principles and holds itself to these same high standards. While we are an Israeli company, the values associated with Dr. King’s legacy resonate worldwide. Our work is guided by a patient-centered approach, focusing on providing the patient with a tailored and minimally-invasive treatment which seeks to maximize quality of life and to respect for human dignity. May Dr. King's legacy be blessed to continue to resonate far and wide.

16/01/2026

J.P. Morgan week is always intense, and this year was no exception. From Sunday on, our CEO U*i Sofer and CFO Raphi Levy were in constant motion, meeting with investors from early morning through late night, making the most of a critical opportunity to share AlphaTau’s story and listen closely to the market.

The week culminated with Raphi taking the stage to present Alpha Tau Medical, delivering a clear message that felt like a fresh start rather than the end of a demanding week.

The high-energy engagement and strong feedback throughout the conference reinforced what we see every day: Alpha Tau is gaining momentum, our differentiated technology and value proposition are resonating well.

14/01/2026

Why a leading dermatology publication has its eyes on the AlphaDaRT®

The last few weeks have been a whirlwind of data and dialogue at ASCO GI and the J.P. Morgan Healthcare Conference. But amid all the conference buzz, a major step towards potential patient access is drawing particular attention in the field of skin cancer.

Dermatology Times recently highlighted Alpha Tau Medical submission to the FDA of the first module of a Pre-Market Approval (PMA) application for the Alpha DaRT as a treatment for recurrent cutaneous squamous cell carcinoma (cSCC), a condition for which treatment options are often exhausted.

As the article cites Dr. Robert Den, MD, our CMO: Alpha DaRT’s “ability to deliver potent, localized alpha radiation directly into the tumor bed allows us to be more aggressive against the cancer than ever before, while remaining conservative with the surrounding healthy skin.”

For skin cancer patients facing “untreatable” cases, Alpha DaRT may provide great benefit. The journey from clinical trial to patient bedside is moving fast.*

*Alpha DART is currently available only in the context of authorized clinical trials.

Check out the full article:
https://lnkd.in/dirjJk3b

13/01/2026

A year has passed… and somehow our CFO and CEO still haven’t mastered ping pong. 🏓

But what they have mastered is building amazing connections and relationships.

From to , we’ve made tremendous progress - advancing our intratumoral radiotherapeutic platform, deepening our clinical and commercial readiness, and positioning Alpha Tau Medical with high potential to lead in a fast-growing market with enormous patient impact.

We arrive at JPMorgan 2026 excited, motivated, and eager to share the many opportunities ahead.

The ping pong skills may still be a work in progress - but the momentum at Alpha Tau is very real.

08/01/2026

Excited to be in San Francisco for 2026!

We are gearing up to attend the Gastrointestinal Cancers Symposium, in what promises to be a highly engaging and fascinating conference. A highlight for us this year will be the presentation by Dr. Corey Miller of the latest Alpha DaRT® results from our trial in Montreal for pancreatic cancer, which we are very excited to share with top leaders in this important field.
Our Business Development Manager, Michael Tolub, is also on-site and eager to connect for those who wish to learn more about our exciting clinical trial program.
Please feel free to reach out here or direct message us to coordinate a time to meet with Michael or Dr. Miller.
Looking forward to meeting you!

06/01/2026

Alpha Tau Medical today announced the release of final results from its first-in-human study in Montreal, Canada exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC). The results have been published as two abstracts and will be presented at the upcoming 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, January 8 – 10, 2026.

“We are very excited about the results of the study, in which we were the first clinicians to deliver Alpha DaRT via ultrasound into the pancreas”, added Dr. Corey Miller. “The results indicate that Alpha DaRT is a technically feasible treatment of pancreatic cancer, with a strong safety profile and encouraging local disease control. We look forward to further exploration of the use of Alpha DaRT for PDAC patients in the IMPACT trial as well as future trials, with the potential to generate a meaningful data set focused on a specific patient population with newly diagnosed disease”.



For the full announcement, please read:

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Showcasing Immune-Preservation and High Disease Control

05/01/2026

Alpha Tau Medical today announced the submission of the first module of its pre-market approval ( ) application to the U.S. Food and Drug Administration ( ), following the FDA’s previous decision to allow the Company to use the more flexible modular approach.

- Initial module submission marks an important milestone in the pre-market approval process -

- Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted -

- Module submitted in parallel to ex*****on of pivotal study (Recurrent SCC Treatment with Alpha DaRT Radiation Therapy), which is expected to complete recruiting patients in Q1 2026 -

For the full announcement, please read -

Alpha Tau announced the submission of the first module of its pre-market approval (PMA) application FDA

25/12/2025

First Alpha DaRT® Treatment at OSU featured in cleveland.com

Nice to see the world’s first use of Alpha DaRT technology in the brain featured in cleveland.com. It’s meaningful to see this important innovation recognized on a major platform, reinforcing both the urgent unmet need in treating recurrent and the promise of Alpha DaRT as a treatment approach, currently only available in .

https://www.cleveland.com/news/2025/12/brain-tumor-breakthrough-first-patient-receives-alpha-dart-radiation-at-osu.html

The James Cancer Hospital's innovative procedure places short-range radiation directly into glioblastoma tumors, addressing the urgent need for localized treatments with fewer side effects.